In vitro evaluation of cancer-specific NF-κB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines

British Journal of Cancer

Volumn 97, Issue 6, 2007, Pages 745-754

  Guo, X ^a   Evans, T R J ^b   Somanath, S ^a   Armesilla, A L ^a   Darling, J L ^a   Schatzlein, A ^c   Cassidy, J ^b   Wang, W ^a  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CEA; Colorectal cancer; GDEPT; NF B; Thymidine phosphorylase

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DOXIFLURIDINE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; THYMIDINE PHOSPHORYLASE;

ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; GENE EXPRESSION; GENE SEQUENCE; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; CYTOMEGALOVIRUS; DNA, COMPLEMENTARY; FLUOROURACIL; GENE THERAPY; HUMANS; NF-KAPPA B; PRODRUGS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYMIDINE PHOSPHORYLASE; TRANSFECTION;

EID: 34548580291     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603930     Document Type: Article

References (38)

1. Aghi M, Hochberg F, Breakefield XO (2000) Prodrug activation enzymes in cancer gene therapy. J Gene Med 2: 148-164
2. Banerji J, Olson L, Schaffner W (1983) A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes. Cell 33: 729-740
3. Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, Longley DB, Johnston PG (2004) Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 10: 2158-2167
4. Chen CJ, Li LJ, Maruya A, Shively JE (1995) In vitro and in vivo footprint analysis of the promoter of carcinoembryonic antigen in colon carcinoma cells: effects of interferon gamma treatment. Cancer Res 55: 3873-3882
5. Ciccolini J, Cuq P, Evrard A, Giacometti S, Pelegrin A, Aubert C, Cano JP, Iliadis A (2001) Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo. Mol Cancer Ther 1: 133-139
6. Ephrussi A, Church GM, Tonegawa S, Gilbert W (1985) B lineage - specific interactions of an immunoglobulin enhancer with cellular factors in vivo. Science 227: 134-140
7. Evans TR, Pentheroudakis G, Paul J, McInnes A, Blackie R, Raby N, Morrison R, Fullarton GM, Soukop M, McDonald AC (2002) A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Ann Oncol 13: 1469-1478
8. Evrard A, Cuq P, Robert B, Vian L, Pelegrin A, Cano JP (1999) Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study. Int J Cancer 80: 465-470
9. Hammarstrom S (1999) The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9: 67-81
10. Hauck W, Stanners CP (1995) Transcriptional regulation of the carcinoembryonic antigen gene. Identification of regulatory elements and multiple nuclear factors. J Biol Chem 270: 3602-3610
11. Huber BE, Austin EA, Richards CA, Davis ST, Good SS (1994) Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91: 8302-8306
12. Karin M (1999) How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 18: 6867-6874
13. Kato Y, Matsukawa S, Muraoka R, Tanigawa N (1997) Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. Br J Cancer 75: 506-511
14. Lan KH, Kanai F, Shiratori Y, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Tanaka T, Ohashi M, Omata M (1996a) Tumor-specific gene expression in carcinoembryonic antigen - producing gastric cancer cells using adenovirus vectors. Gastroenterology 111: 1241-1251
15. Lan KH, Kanai F, Shiratori Y, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Tanaka T, Ohashi M, Omata M (1996b) Tumor-specific gene expression in carcinoembryonic antigen - producing gastric cancer cells using adenovirus vectors. Gastroenterology 111: 1241-1251
16. Li F, Altieri DC (1999) Transcriptional analysis of human survivin gene expression. Biochem J 344(Part 2): 305-311
17. Malet-Martino M, Martino R (2002) Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 7: 288-323
18. Manome Y, Watanabe M, Abe T, Tomita M, Watanabe S, Yokokawa Y, Takahashi Y, Ishii K, Kimura A, Murakami M, Nagata M, Shibata T, Nakamura M, Tanigawa N, Ohno T (2001) Transduction of thymidine phosphorylase cDNA facilitates efficacy of cytosine deaminase/5-FC gene therapy for malignant brain tumor. Anticancer Res 21: 2265-2272
19. Nabel G, Baltimore D (1987) An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326: 711-713
20. Nelms K, Hromas R, Van Ness B (1990) Identification of a second inducible DNA-protein interaction in the kappa immunoglobulin enhancer. Nucleic Acids Res 18: 1037-1043
21. Nyati MK, Sreekumar A, Li S, Zhang M, Rynkiewicz SD, Chinnaiyan AM, Rehemtulla A, Lawrence TS (2002) High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. Cancer Res 62: 2337-2342
22. Patterson AV, Zhang H, Moghaddam A, Bicknell R, Talbot DC, Stratford IJ, Harris AL (1995) Increased sensitivity to the prodrug 5′-deoxy-5- fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 72: 669-675
23. Perkins ND, Edwards NL, Duckett CS, Agranoff AB, Schmid RM, Nabel GJ (1993) A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J 12: 3551-3558
24. Petty RD, Cassidy J (2004) Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy. Curr Cancer Drug Targets 4: 191-204
25. Plumb JA, Milroy R, Kaye SB (1989) Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 49: 4435-4440
26. Rayet B, Gelinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18: 6938-6947
27. Richards CA, Austin EA, Huber BE (1995a) Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 6: 881-893
28. Richards CA, Austin EA, Huber BE (1995b) Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 6: 881-893
29. Rooseboom M, Commandeur JN, Vermeulen NP (2004) Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56: 53-102
30. Sassone-Corsi P, Hen R, Borrelli E, Leff T, Chambon P (1983) Far upstream sequences are required for efficient transcription from the adenovirus-2 E1A transcription unit. Nucleic Acids Res 11: 8735-8745
31. Schrewe H, Thompson J, Bona M, Hefta LJ, Maruya A, Hassauer M, Shively JE, von Kleist S, Zimmermann W (1990) Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression. Mol Cell Biol 10: 2738-2748
32. Shively JE, Beatty JD (1985) CEA-related antigens: molecular biology and clinical significance. Crit Rev Oncol Hematol 2: 355-399
33. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, Inoue M (1999) Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59: 551-557
34. Teferedegne B, Green MR, Guo Z, Boss JM (2006) Mechanism of action of a distal NF-kappaB-dependent enhancer. Mol Cell Biol 26: 5759-5770
35. Ueda K, Iwahashi M, Nakamori M, Nakamura M, Matsuura I, Yamaue H, Tanimura H (2001) Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res 61: 6158-6162
36. Wang W, Cassidy J (2003) Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. Br J Cancer 88: 624-629
37. Wang W, McLeod HL, Cassidy J (2003) Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 104: 504-511
38. Yoshimura A, Kuwazuru Y, Furukawa T, Yoshida H, Yamada K, Akiyama S (1990) Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors. Biochim Biophys Acta 1034: 107-113